This review highlights future directions in antiarrhythmic drug therapy for atrial fibrillation, focusing on modifying existing agents and targeting new mechanisms.
May guide future AF drug trials; leaves open which agents will prove safe and effective in practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Musco et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: